Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection

Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection

SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Current Good Manufacturing Practices) on-site...

PharmaBlock Launches Commercial GMP Workshop 503 at Zhejiang Site

PharmaBlock Launches Commercial GMP Workshop 503 at Zhejiang Site

NANJING, China, Feb. 18, 2025 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE) has announced the official launch of its commercial GMP Workshop 503 (W503) at PharmaBlock Zhejiang. The new workshop significantly enhances...

menu
menu